Content about Sagent Advisors

March 20, 2013
Sagent appoints James Hussey as president

Generic drug maker Sagent Pharmaceuticals has appointed James Hussey as its president, the company said.

SCHAUMBURG, Ill. — Generic drug maker Sagent Pharmaceuticals has appointed James Hussey as its president, the company said.

Sagent said the board of directors' appointment of Hussey, 53, would be effective Monday. Hussey will be responsible for the company's commercial operations, including development, regulatory affairs, supply chain activities, sales, marketing and human resources.

October 3, 2012
Sagent launches drug for apnea of prematurity in infants

Sagent Pharmaceuticals has launched a drug used to treat apnea of prematurity in infants, the drug maker said Wednesday.

SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched a drug used to treat apnea of prematurity in infants, the drug maker said Wednesday.

Sagent announced the launch of caffeine citrate injection and caffeine citrate oral solution, used to treat apnea of prematurity in infants between 28 and less than 33 weeks gestational age.

The market for the drug was worth about $28.5 million during the 12-month period ended in July, according to IMS Health. The drug features Sagent's PreventIV Measures packaging and labeling, which are designed to reduce medication errors.

September 11, 2012
Sagent launches drug to prevent chemotherapy-induced vomiting

Sagent Pharmaceuticals has launched a drug used to treat complications related to chemotherapy, the drug maker said.

 SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched a drug used to treat complications related to chemotherapy, the drug maker said.

The Schaumburg, Ill.-based company announced the launch of ondansetron injection, used to prevent nausea and vomiting associated with emetogenic cancer chemotherapy and also to prevent nausea and vomiting that follows surgery.

Various versions of the drug had sales of $49 million during the 12-month period that ended in June, according to IMS Health.

August 9, 2012
Sagent Pharmaceuticals launches oxaliplatin

Drug maker Sagent Pharmaceuticals has launched a generic chemotherapy drug, the company said Thursday.

SCHAUMBURG, Ill. — Drug maker Sagent Pharmaceuticals has launched a generic chemotherapy drug, the company said Thursday.

Sagent announced the launch of oxaliplatin, a generic version of Sanofi's Eloxatin.

Various versions of the drug had sales of about $1.7 billion during the 12-month period ended in June, according to IMS Health.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

July 25, 2012
Sagent launches generic antibiotic

Sagent Pharmaceuticals has launched a generic antibiotic, the company said.

SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched a generic antibiotic, the company said.

The generic drug maker announced the launch of oxacillin for injection. The drug is a semi-synthetic penicillin used to treat infections caused by penicillinase-producing staphylococci bacteria that have demonstrated susceptibility to the drug.

The drug had sales of $29 million during the 12-month period ended in May, according to IMS Health.

May 17, 2012
Sagent launches generic chemotherapy drug

Sagent Pharmaceuticals has launched a generic version of a chemotherapy drug, the company said Thursday.

SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched a generic version of a chemotherapy drug, the company said Thursday.

Sagent announced the launch of irinotecan injection, a generic version of Pfizer's Camptosar, in latex-free, preservative-free, single-dose vials.

Various versions of the drug had sales of about $28 million during the 12-month period ended in March, according to IMS Health.

November 7, 2011
Sagent Q3 net revenue jumps 94%

Third-quarter net revenue for Sagent Pharmaceuticals jumped 94% to $41.3 million, thanks to several new product launches during the period.

SCHAUMBURG, Ill. — Third-quarter net revenue for Sagent Pharmaceuticals jumped 94% to $41.3 million, thanks to several new product launches during the period.

Gross profit for the quarter ended Sept. 30 was $6.9 million, or 16.8% of net revenues, compared with $2.7 million, or 12.9% of net revenues, in the year-ago period.

October 3, 2011
FDA approves Sagent antibiotic

The Food and Drug Administration has approved a generic antibiotic made by Sagent Pharmaceuticals, Sagent said.

SCHAUMBURG, Ill. — The Food and Drug Administration has approved a generic antibiotic made by Sagent Pharmaceuticals, Sagent said.

The drug maker announced the approval of clindamycin injection, which the company said was the 12th product approved under its joint venture with Strides Arcolab, under which Strides is responsible for developing and supplying injectable products that Sagent markets in the United States.

The market for injectable clindamycin this year is about $65 million, according to IMS Health.

September 28, 2011
Sagent's chemotherapy drug enters market

Sagent Pharmaceuticals has launched its new chemotherapy drug.

SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched its new chemotherapy drug.

Sagent sent that its paclitaxel injection USP is available in 30-mg, 100-mg and 300-mg latex-free, multi-dose vials. Paclitaxel is indicated for use alone or with other drugs to treat ovarian cancer, breast cancer, non-small cell lung cancer and AIDS-related Kaposi's sarcoma, Sagent said.

September 1, 2011
FDA approves Sagent drug

The Food and Drug Administration has approved a generic skeletal muscle relaxant made by Sagent Pharmaceuticals, Sagent said.

SCHAUMBURG, Ill. — The Food and Drug Administration has approved a generic skeletal muscle relaxant made by Sagent Pharmaceuticals, Sagent said.

The generic drug maker announced the approval of orphenadrine citrate injection, which it will offer in 60-mg-per-2-mL, single-dose vials.

Various versions of the drug had sales of about $4.3 million in 2011, according to IMS Health.

August 30, 2011
Sagent names new CFO

Jonathon Singer has been appointed CFO of Sagent Pharmaceuticals, the generic drug maker said.

SCHAUMBURG, Ill. — Jonathon Singer has been appointed CFO of Sagent Pharmaceuticals, the generic drug maker said.

Singer joins Sagent from Landauer, a leader in radiation sciences and services, where he served as SVP finance and CFO. Meanwhile, Sagent's current CFO, Ron Pauli, will be transitioned into a newly created role of chief business officer, where he will be responsible for product launch execution, product pipeline management and business development.

August 19, 2011
Sagent launches neuromuscular disorder drug

Generic drug maker Sagent Pharmaceuticals has launched a new drug for neuromuscular disorders, the company said.

SCHAUMBURG, Ill. — Generic drug maker Sagent Pharmaceuticals has launched a new drug for neuromuscular disorders, the company said.

Sagent announced the launch of vecuronium bromide, an injectable drug used to treat myasthenia gravis and Eaton-Lambert syndrome. The disorders cause muscle weakness and fatigue.

The market for vecuronium bromide is about $10 million in the United States, according to IMS Health.

December 3, 2010
With drug's FDA approval, Sagent expands oncology portfolio

The Food and Drug Administration has approved a generic chemotherapy drug made by Sagent Pharmaceuticals, Sagent said Thursday.

SCHAUMBURG, Ill. — The Food and Drug Administration has approved a generic chemotherapy drug made by Sagent Pharmaceuticals, Sagent said Thursday.

The FDA approved topotecan hydrochloride for injection, a version of GlaxoSmithKline’s Hycamtin. The U.S. market for injectable topotecan was around $158 million in 2010, according to IMS Health.

October 5, 2010
Sagent's injectable antibiotics enter market

Generic drug maker Sagent Pharmaceuticals has launched two injectable antibiotics, the company said Tuesday....

SCHAUMBURG, Ill. Generic drug maker Sagent Pharmaceuticals has launched two injectable antibiotics, the company said Tuesday.

 

Sagent announced the launch of ampicillin and ampicillin with sulbactam. Ampicillin had sales of around $42 million during the 12-month period ended in June, while ampicillin with sulbactam had sales of around $40 million during the same period, according to IMS Health.

 

 

August 1, 2010
Sagent's generic Imitrex receives regulatory approval

The Food and Drug Administration has approved a generic injected drug made by Sagent Pharmaceuticals...

SCHAUMBURG, Ill. The Food and Drug Administration has approved a generic injected drug made by Sagent Pharmaceuticals for treating migraine attacks, Sagent said Monday.

 

The FDA approved Sagent’s sumatriptan succinate injection in the 6 mg per 0.5 milliliter strength. The drug is used to treat acute migraine attacks and cluster headache episodes.

 

 

Sumatriptan is a generic version of GlaxoSmithKline’s Imitrex. Injectable sumatriptan had $22 million in sales in 2009, according to IMS Health.

May 17, 2010
Sagent recalls lots of generic antibiotic

Generic drug maker Sagent Pharmaceuticals is recalling all its lots of an injectable antibiotic due...

May 9, 2010
Actavis, Sagent partner to develop and market injectable drugs

Actavis and Sagent Pharmaceuticals have agreed to develop and market a group of injectable drugs...